Key result
ACE inhibitors, ARBs, nebivolol, and statins preserve erectile function, while non-selective beta-blockers worsen it.
Why the study?
Pharmacotherapy for metabolic syndrome must be safe as well as effective, motivating an evaluation of how drugs used to treat cardio-metabolic disorders affect erectile function in men.
Does pharmacotherapy for metabolic syndrome components affect erectile function in men with metabolic syndrome?
Does pharmacotherapy for metabolic syndrome components affect erectile function in men with metabolic syndrome?
Selecting cardiometabolic pharmacotherapies with favorable or neutral erectile profiles—such as ACE inhibitors, ARBs, CCBs, statins, and nebivolol—over agents that impair erectile function like non-selective beta-blockers and potassium-sparing diuretics is critical for maintaining treatment adherence and quality of life in men with metabolic syndrome.
Answers are grounded in this paper and cite their sources.
May guide cardiometabolic drug selection to preserve erectile function; leaves open prospective randomized confirmation.
Metabolic syndrome (MS) is still an urgent medical and social problem, although its definitions, criteria, diagnostic and therapeutic options have long been clearly regulated in the clinical recommendations of various scientific communities. However, any pharmacotherapy should be not only effective, but also safe. Aim. The literature review, based on the results of modern evidence-based studies, examines the problem of the possible effect of drug treatment of various cardio-metabolic disorders (components) that make up the essence of MS on the erectile function of men. Detailed information is provided on the possible effect and its mechanisms of the main classes of drugs traditionally used to correct key components of MS (antihypertensive drugs (various classes), dyslipidemic drugs (statins), drugs for the correction of insulin resistance and type 2 diabetes mellitus (biguanides – metformin)). Key points. A literature review has demonstrated the neutral effect of calcium channel blockers (calcium antagonists), the positive effect of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers, as well as the neutral or even positive effect of statins on erectile function in men with MS. The ‘old’ (non-selective) beta-blockers are still considered as the class of drugs that are most often associated with ED, however, the new selective beta-blocker nebivolol demonstrates a positive effect on the erectile function of men with hypertension. The ‘erectile’ safety of diuretics obviously depends on the class of drugs. Thus, aldosterone agonists (potassium-sparing diuretics) have a convincing evidence base for their negative effect on erectile function in men, while thiazide and loop diuretics show only certain erectile deterioration trends in some patients, which need to be evaluated in future evidence-based studies. For biguanides (metformin), the results of experimental studies showing the positive effect of these drugs on erectile function in animals often do not coincide with the results of clinical studies, which demonstrate completely multidirectional and contradictory changes in erectile function in men treated with these drugs: from improving erection to the ability to exacerbate existing ED, which is due to the lack of a portion of large RCTs. Conclusion. Practical information on the ‘erectile’ safety of various classes of drugs for the treatment of MS components plays a critically important role for clinicians involved in the treatment of MS in men, in whom the maintenance or improvement of erectile function during treatment is accompanied by a significant increase in commitment to its continuation on an ongoing basis, improves the final results of pharmacotherapy of MS and ED, and eventually – men’s quality of life.
No takes yet. Share an insight, caveat, or question.
Греков et al. (2026) conducted a review in Metabolic syndrome and erectile dysfunction. Pharmacotherapy for metabolic syndrome (ACE inhibitors, ARBs, calcium channel blockers, beta-blockers, diuretics, statins, metformin) was evaluated on Erectile function / risk of erectile dysfunction. ACE inhibitors, ARBs, nebivolol, and statins preserve or improve erectile function in men with metabolic syndrome, whereas non-selective beta-blockers and aldosterone antagonists worsen it.
Synapse has enriched 10 related papers. Consider them for comparative context: